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Abstract 
Background 
There is a paucity of longitudinal research investigating vitamin D in people with early 
psychosis.  
Method 
Vitamin D levels were measured in 168 patients (64%(n=108) male, mean age 
29.3(9.8)years)with first episode psychosis (FEP), along with measures of clinical state at 
baseline and at 12 months follow up. 
We assessed the a) cross sectional, and; b) longitudinal relationships between continuous 
and categorical 25-hydroxyvitamin D (25(OH)D) levels and clinical symptoms at first contact 
for psychosis and at 12 months. 
Results 
In FEP, 80% (n=134) at baseline, and 76% at 12 months follow up, had suboptimal vitamin 
D levels (<20 ng/ml). Suboptimal levels of 25 (OH) D at baseline were not cross-sectionally 
associated with clinical symptoms. Higher vitamin D levels at baseline (n=77)  were 
significantly associated with better visual reproduction-immediate recall (β=0.249, 95%CI=-
0.012-0.871,p=0.044).  
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Higher baseline vitamin D levels were prospectively associated with lower total PANSS (β=-
0.24,95%CI=-0.47—0.01, p=0.04) and PANSS negative symptom scores ((β=-0.12,95%CI=-
0.23—0.01, p=0.04) at 12 months. 
Conclusion  
We identified a prospective association between higher baseline serum Vitamin D levels and 
lower total psychotic symptoms and negative symptoms of psychosis at 12 months after first 
contact for psychosis. The results of this study require replication in larger prospective 
studies, and highlight the need for large randomised trials to assess the effect of vitamin D 
supplementation on symptoms of psychosis in FEP. 
Keywords: 25-hydroxyvitamin D (25(OH)D); FEP; schizophrenia; longitudinal; negative 
symptoms; cognitive ; psychosis 
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1. Introduction 
Vitamin D is a secosteroid hormone which functions as a neuroprotective factor, with a role 
to play in neuroimmunomodulation, regulation of neurotrophic factors and brain development 
(Eyles et al., 2013; Harms et al., 2008). Vitamin D is primarily acquired through cutaneous 
synthesis under the action of ultraviolet (UV) sunlight (Holick, 2004) and to a variable but 
much lesser extent from nutritional sources. Vitamin D levels thus reflect ambient levels of 
sunlight (Hypponen and Power, 2007). An increased risk of developing schizophrenia is 
seen in settings where sunlight may be relatively low - higher latitudes (Gupta and Murray, 
1992; Jongsma et al., 2018; Saha et al., 2006) and urban settings (Mortensen et al., 1999; 
Peen et al., 2010), with a higher prevalence of psychosis seen in Black African or Black 
Caribbean migrant groups in the UK (Fearon et al., 2006). Vitamin D during 
neurodevelopment may be important - Winter/ Spring births confer a higher risk of psychosis 
(Davies et al., 2003), while a Danish longitudinal case-control study has found that vitamin D 
in neonates is associated with the risk of developing schizophrenia in adult life (McGrath et 
al., 2010).  
Vitamin D levels are sub-optimal in people with established schizophrenia and other 
psychotic disorders(Adamson et al., 2017), being lower than matched controls even from the 
first episode of psychosis (Crews et al., 2013; Firth et al., 2017). In the two largest cross 
sectional studies of Vitamin D in established psychotic disorders, levels of suboptimal 
Vitamin D (vitamin D insufficiency and deficiency) of 90% (Lally et al., 2016)  and 46% 
(Suetani et al., 2017) have been recorded. Suboptimal vitamin D in schizophrenia and 
psychotic disorders is increasingly recognised as a widespread problem (Valipour et al., 
2014) .  
Relationships between vitamin D and psychotic symptoms, both positive and negative have 
been reported in established schizophrenia (Adamson et al., 2017; Berg et al., 2010; Cieslak 
et al., 2014; Dogan Bulut et al., 2016; Nerhus et al., 2016), though the largest cross sectional 
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study of 324 patients with established psychotic disorders did not replicate these findings 
(Lally et al., 2016). The most consistent findings in people with mental disorders have been 
associations between lower vitamin D levels and depression (Anglin et al., 2013). Inverse 
correlations between vitamin D levels and depressive symptoms have been identified in 
some cross sectional studies in established psychosis (Berg et al., 2010; Nerhus et al., 
2016), but this is an equivocal finding (Itzhaky et al., 2012; Lally et al., 2016).   
Considerably less is known about clinical correlates of low vitamin D in FEP compared to 
those with established psychosis.  Low vitamin D levels were associated with negative 
symptoms and more severe cognitive deficits in 20 people with first episode schizophrenia 
(FES) (Graham et al., 2015). These findings were supported by a cross sectional study of 31 
FEP patients, in which a similar inverse correlation between vitamin D levels and negative 
symptoms was identified (Yee et al., 2016). A somewhat larger study with 71 FEP patients 
did not identify significant correlations between vitamin D and psychotic symptoms, but did 
identify significant correlations with depressive symptoms (Nerhus et al., 2015). Associations 
with clinical state have been demonstrated in adolescents who are 3.5 times more likely to 
have psychotic symptoms when vitamin D deficient (Gracious et al., 2012).  
Cognitive deficits are a recognised feature of psychotic disorders, evident prior to the onset 
of illness and with impairment in processing speeds, verbal and working memory and 
executive functioning the most consistent deficits found (Fatouros-Bergman et al., 2014; 
Howes et al., 2015; Nerhus et al., 2017; Zanelli et al., 2010). The neurobiology underlying 
the cognitive impairment seen in psychotic disorders is unclear (Howes et al., 2015). The 
role of Vitamin D in brain development and functioning supports the hypothesis that 
hypovitaminosis D could contribute to cognitive impairments. While the relationship between 
low vitamin D levels and worse cognitive function is best established in the elderly (van der 
Schaft et al., 2013), the association in those with psychosis remains uncertain. A cross 
sectional association between Vitamin D insufficiency and more severe cognitive deficits (as 
measured by overall cognitive score) in twenty cases of FES was identified (Graham et al., 
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2015). Of the individual cognitive measures, only verbal fluency was related to low vitamin D 
status, although once adjusted for age, the relationship no longer remained significant. 
Cognitive function was not correlated with Vitamin D status in healthy controls. In a cross 
sectional study of 225 people with psychotic disorders, vitamin D deficiency was associated 
with decreased processing speed and decreased verbal fluency (Nerhus et al., 2017).  
A major limitation of work to date exploring the relationship between vitamin D and clinical 
state in people FEP is that to the best of our knowledge no longitudinal study exists, 
precluding inferences on the directionality between vitamin D and clinical status. Further, 
while previous cross sectional studies of small sample size have assessed the relationship 
between vitamin D and psychotic and depressive symptoms, only one has explored the 
relationship with cognition. 
1.2 Study aims: 
Clinical remission and recovery in FEP remains suboptimal (Lally et al., 2017a) and in the 
current study, we sought to clarify whether serum vitamin D (25-hydroxyvitamin D 
(25(OH)D)) levels are prospectively associated with psychotic and depressive symptoms at 
12 months after first contact for FEP.  
Given the paucity of research investigating vitamin D in people with early psychosis, we set 
out to examine a) the cross sectional relationship between vitamin D and clinical state and 
cognitive measures at first contact for psychosis; b) the relationship between baseline 
vitamin D status and depressive and psychotic symptoms at 12 months; and c) the 
prevalence of vitamin D deficiency and insufficiency during the first year of treatment for 
psychosis.   
We hypothesized that baseline 25(OH)D serum levels are cross sectionally associated with 
clinical state measures in FEP, and that lower vitamin D levels at baseline would be 
inversely associated with depressive and psychotic symptoms at 12 months.   
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2. Methods:  
2.1 Study participants and design 
A prospective observational study of 168 adults (108 males) with a first episode psychosis 
(FEP), recruited as part of a prospective observational cohort study, Physical health and 
substance Use Measures in first onset Psychosis (PUMP), part of the National Institute of 
Health Research funded IMPACT programme (grant RP-PG-0606-1049).  
All participants were included in the study after written, informed consent and the study 
protocol was approved by the Research Ethics Committee (08/H0807/53) Patients were 
assessed at baseline and after 1 year of follow-up. 
2.2 Eligibility criteria 
Inclusion Criteria were as follows: a) aged between 18 and 65; b) met the ICD-10 criteria for 
FEP (codes F20-29 and F30-33) (World Health Organization, 1992) and; c) understood 
English and did not require an interpreter.  
Patients were excluded if they: were pregnant or had a major medical illness or neurological 
disease; met the criteria for organic psychosis (F09) or presented with evidence of transient 
psychotic symptoms resulting from acute intoxication as defined by ICD-10; or diagnosed 
with a moderate or severe learning disability (as defined by ICD-10, World Health 
Organization, 1992) (World Health Organization, 1992); or had a history of previous contact 
with health (GP or psychiatric) services for psychosis(Lally et al., 2017b). 
2.3 Recruitment 
Patients were recruited as soon after first presentation as possible and were followed up 
prospectively over a twelve-month period during which they remained under the care of 
mental health teams.  The baseline diagnoses were made from face-to-face interviews and 
mental health records according to ICD-10 criteria (World Health Organization, 1992) 
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utilising the Operational Criteria Checklists (OPCRIT) (McGuffin et al., 1991). Individuals with 
comorbid substance use disorders were not excluded. 
2.4 Outcome measures 
2.4.1 Serum Vitamin D measurement and categorisation  
Serum Vitamin D levels (serum 25(OH)D) were measured at baseline and at one year, using 
chemiluminescence immunoassay (DiaSorin, S.P.A. Saluggia (Vercelli), Italy). Vitamin D 
insufficiency was defined as vitamin D levels between 10-20 ng/ml while levels below 
10ng/ml were classed as vitamin D deficiency(Dawson-Hughes et al., 2010). A serum level 
of greater than 20 ng/ml (equivalent to >50 nmol/L) was considered optimal (Pearce and 
Cheetham, 2010). We further categorised vitamin D as quartiles, replicating previous 
work(Jovanova et al., 2017), to ensure that we were able to assess the effects vitamin D 
across its range of values.   
2.4.2 Demographic data and clinical outcome measures 
Baseline data included demographics, age, sex, ethnicity (self-report), and diagnoses. 
Clinical state measures were recorded at baseline and at 12 months follow up. The severity 
of psychopathology was rated on the Positive and Negative Symptom Scale (PANSS) (Kay 
et al., 1989) and by the Global Assessment of Functioning (GAF) scale at first presentation 
for psychosis. Mood symptoms were assessed using the Calgary Depression score 
(Addington et al., 1990), and the Young Mania Rating Scale (YMRS) (Young et al., 1978). 
The assessment of psychopathology and cognition was completed blind to vitamin D status.  
2.4.3 Neurocognitive assessment  
A subset of 88 patients at baseline were administered a neurocognitive battery to assess 
cognitive functioning. The battery comprised assessments from the Wechsler Adult 
Intelligence Scale – Third Edition (WAIS-III) and the Wechsler Memory Scale – Third Edition 
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(WMS-III). The following tests were used from the WAIS-III battery: block design; matrix 
reasoning; digit symbol coding; information; and digit span. The following tests were used 
from the WMS-III battery: verbal fluency; trail making; logical memory; visual reproduction; 
and spatial span. Two subtasks from the computerised Cambridge Neuropsychological Test 
Automated Battery (CANTAB) were administered to 54 patients within the subset: the 
Stockings of Cambridge (SoC) (Sahakian and Owen, 1992) and the Spatial Working Memory 
(SWM) (Sahakian and Owen, 1992) task. The SoC is a spatial planning task measuring 
executive function. The SWM is a test of working memory and in particular measures an 
individual’s ability to retain and manipulate stored information. The National Adult Reading 
Test (NART) (Nelson and Willison, 1991)was used as an estimate of general IQ. 
 
2.5 Confounding factors 
The following proposed confounding factors were evaluated: gender, age, and season of 
sampling. We used the season of blood sampling as a proxy for sunlight irradiation, as it is a 
factor which will affect the duration and intensity of sunlight exposure. We defined the 
seasons as follows: Summer: June to August; Autumn: September-November; Winter: 
December to February; Spring: March-May. 
2.6 Data Analysis 
2.6.1. Multiple imputation.  
Serum 25(OH)D level (ng/ml), ethnicity and gender were the only variables in the dataset 
that did not have any missing information. It has now been recognised that complete case 
analysis without adequate handling of missing data may lead to biased results,  or reduced 
power and precision of estimates (Zhao and Long, 2016). We assumed that the missing 
variables were missing at random (MAR). The assumption is that the propensity for 
missingness in our dataset was not linked to the unobserved values, and only dependent on 
observed data. We imputed the missing values using multiple imputation by chained 
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equations (MICE) (Deng et al., 2016). MICE has been shown to be a robust method for 
dealing with missing data across empirical and longitudinal studies (He et al., 2011; Zhao 
and Long, 2016). In the MICE procedure a series of regression models are run whereby 
each variable with missing data is modelled according to its distribution (Azur et al., 2011); 
for continuous variables, this would be a multivariable linear regression; and for binary 
variables, a logistic regression. To increase the precision of the imputed data and 
subsequent perditions, we imputed all variables of interest including outcomes and 
confounding variables (Schafer and Graham, 2002) and additionally included auxiliary 
variables (Collins et al., 2001) such as baseline diagnoses and ethnicity. We used 25 sets of 
imputations (White et al., 2011); each imputed dataset was then analysed separately using 
standard complete-data analysis methods and the results were combined across all imputed 
datasets using Rubin’s rule (Rubin, 1996). In the present study, we conducted multiple 
imputation using the MICE package (Van Buuren, 2011) in R. The proportion of outcome 
meaures imputed compared to observed is shown in supplementary table 1.  
2.6.2. Descriptive and association analyses.  
Between groups comparisons were made using Χ2 test for categorical variables; 
independent student’s t-test for continuous variables, or the Mann-Whitney U test if variables 
were not normally distributed. Linear regression was used to test the hypothesis that 
baseline vitamin D levels were related to clinical state at 12 months, by examining the 
association between baseline serum vitamin D levels and the 12-month PANSS, GAF, 
CDRS, and YMRS scores controlling for potential confounding factors of gender, age, 
season of sampling at baseline, and the corresponding baseline clinical variable. Statistical 
significance was defined as p<0.05. All analyses were conducted in RStudio version	  
0.99.486 (Integrated Development for R. RStudio, Inc., Boston, MA).  
Of the subset of 88 patients administered the neurocognitive battery at baseline, 76 had 
baseline 25(OH)D serum levels recorded. An exploratory analysis was conducted examining 
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the linear correlation between each individual baseline neurocognitive test and baseline 
25(OH)D serum levels using Pearson’s correlation coefficient. For those neurocognitive tests 
which were significantly correlated (p<0.05) with 25(OH)D serum levels ,separate linear 
regressions were run adjusting for age, gender and season of sampling as potential 
confounding factors.  
 
3. Results 
Demographic and clinical characteristics of participants and the relationships with Vitamin D 
status are shown in table 1 and table 2.  Nearly half the participants were of white ethnicity 
(n=78; 46%), with a large minority of participants of black ethnicity (n=61; 36%). Forty two 
percent (n=71) were vitamin D deficient (<10 ng/mL) at study recruitment, 37.5% (n=63) 
were vitamin D insufficient (10-20 ng/mL), and 20.2% (n=34) had sufficient vitamin levels 
(>20 mcg/L). The mean 25-OHD serum level was 13.8 (SD 9.3) ng/ml (range 4.0−67.9 
ng/ml).  
Those with suboptimal vitamin D levels at study recruitment were more likely to be of Black 
ethnicity (n=57; 93% with suboptimal vitamin D levels) (Χ2=15.73, p<0.001) and to have had 
blood sampling in winter (n=32; 97% with suboptimal vitamin D levels) (Χ2=12.65, p=0.005).  
Those who were inpatients at baseline had a significantly higher mean vitamin D level (15.8 
(11.6) ng/ml than outpatients (mean level= 12.2 (6.9) ng/ml) (t=2.039, p=0.044).  
3.1 Neurocognition subgroup  
The associations between 25-OHD levels and demographic and clinical features in the 
subgroup in which neurocognitive measures were performed at baseline (n=76) are shown 
in supplementary table 2. The mean 25-OHD serum level was 12.95 (SD 8.1) ng/ml (range 
4.0−41.3 ng/ml).  
3.2 Vitamin D status at 12 months 
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Eighty four percent had suboptimal vitamin D levels at 12 months follow up; 45.8% (n=77) 
with vitamin D deficiency (<10 mcg/L); 36.9% (n=62) with vitamin D insufficiency (25-OHD 
level of 10-20 mcg/L) and 17.3% (n=29) with optimal vitamin D levels). The mean serum 
vitamin D level at 12 months was 12.2 (SD=8.5) ng/ml (range=4.0-71.9 mcg/L). 
3.3 Cross sectional analysis at baseline 
The cross-sectional analysis of the relationship between baseline 25(OH)D serum levels and 
baseline clinical state, including depressive and psychotic symptoms is presented in Table 1. 
We did not identify any association between 25(OH) D serum levels, analysed either as a 
binary variable (optimal and suboptimal vitamin D) or as quartiles, and clinical state 
measures. 
Cross-sectional analysis of the relationship between baseline 25(OH)D serum levels and 
neurocognitive assessments yielded statistically significant unadjusted associations with 
seven cognitive tests encompassing verbal memory, non-verbal memory and executive 
functioning (supplementary table 3). When adjusted for age, gender and season of sampling, 
only an association between higher vitamin D levels and visual reproduction - immediate 
recall (predominantly testing non-verbal memory) remained statistically significant (β=0.249, 
95% CI=-0.012-0.871, p=0.044).  
3.4 Longitudinal analysis  
Next, we assessed the longitudinal relationship between baseline 25(OH)D serum levels (as 
a continuous measure and quartiles) and 12-month depressive and psychotic symptoms, as 
well as general functioning at 12 months after study recruitment (see tables 3-4). 
Higher levels of 25 (OH) D at baseline were associated with reduced total PANSS score 
(B=-0.24, 95%CI=-0.47- -0.01, p=0.04) and reduced PANSS negative symptom scores ((B=-
0.12, 95%CI=-0.23— -0.01, p=0.04) at 12 months (table 3). 
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When analyzing 25 (OH) D serum level in quartiles, we found no significant prospective 
relationship with 12-month clinical state measures, including psychotic and depressive 
symptoms (table 4).  
Longitudinal changes in serum 25(OH) D levels were not associated with clinical state 
outcome scores at 12 months (see supplementary table 4). There was no significant 
association between the change in serum 25 (OH) levels and changes in psychotic 
symptoms as measured by the PANSS or depressive symptoms as measured by the 
Calgary Depression Scale score over the first 12 months of illness, when adjusting for 
gender, age, and season of baseline 25(OH) D sampling. 
 
4. Discussion 
4.1 Vitamin D and clinical symptoms  
This is the first longitudinal study to assess the relationship between serum vitamin D at first 
presentation with psychosis and clinical state measures 12 months later. In our longitudinal 
analysis, we identified a significant inverse relationship between baseline serum vitamin D 
levels and both total psychotic symptoms, and negative symptoms of psychosis at 12 
months follow up. This is the first report of an association between higher baseline vitamin D 
levels and improved clinical outcomes at one year. Further we conducted the largest cross 
sectional analysis of vitamin levels and clinical symptoms in FEP, in which we failed to 
identify a cross sectional relationship between depressive or psychotic symptoms and mean 
serum vitamin D levels or vitamin D deficiency, unlike earlier studies.  
The lack of an association between vitamin D levels (both categorical and continuous) and 
negative symptoms of psychosis at baseline, but the identified association with negative 
symptoms at 12 months, raise the possibility that low vitamin D at onset of psychosis may be 
associated with the later emergence of negative symptoms. Like previous work in FEP, we 
failed to identify a cross sectional relationship between vitamin D levels and positive 
	   17	  
(Graham et al., 2015; Nerhus et al., 2015; Yee et al., 2016) or negative symptoms (Nerhus 
et al., 2015).  
4.2 Vitamin D and negative symptoms 
We identified that higher baseline vitamin D levels were associated with improved negative 
symptoms at 12 months follow up. Vitamin D is thought to be neuroprotective, with brain 
antioxidant properties, and anti-inflammatory effects, potentially improving negative 
symptoms secondary to unmitigated oxidative stress(Mitra et al., 2017; Nerhus et al., 2016; 
Wrzosek et al., 2013). There remains a significant unmet need in the management of 
negative symptoms, with no treatment having consistent replicated efficacy in treating 
negative symptoms. Though preliminary, our findings raise the prospect of benefits of 
optimising vitamin D levels in early psychosis and ameliorating negative symptoms of 
psychosis.  
4.3 Vitamin D and cognitive function 
Our exploratory study on the cross-sectional relationship of cognitive functioning and 
baseline vitamin D levels is likewise an important addition to earlier work. At unadjusted 
levels, the statistically significant neurocognitive test correlates were consistent with existing 
associations of decreased processing speeds, memory deficits and poor executive 
functioning in those with psychotic illness. However, we did not replicate the previously 
identified association between vitamin D and reduced verbal fluency in those with FEP 
(Graham et al., 2015; Nerhus et al., 2017). When adjusted, we demonstrated a statistically 
significant association between higher levels of vitamin D and improved nonverbal memory. 
A randomised trial (n=82) (2017) investigating the effects of high dose vitamin D 
supplementation on cognition in healthy adults demonstrated significantly improved 
performance in nonverbal (visual) memory tasks with high dose vitamin D supplementation, 
more so than in other cognitive domains (Pettersen, 2017). An RCT investigating he use of 
high dose oral vitamin D in people with schizophrenia treated with clozapine found that those 
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treated with 14,000 IU of vitamin D (n=24 ) had significantly improved delayed recall 
(memory) and attention scores , though this effect was lost after correcting for multiple 
comparisons compared to placebo treated cases (n=23) (Krivoy et al., 2017). The identified 
association between 25(OH)D serum levels and nonverbal memory in our study replicates 
findings from previous general population observational  studies (Darwish et al., 2015; 
Kuzma et al., 2016). It is postulated that the association reflects nonverbal memory’s greater 
cognitive demand and dependence upon executive functioning (Pettersen, 2017).    
4.4 Prevalence of vitamin D insufficiency/deficiency 
We identified that 80% (n=134) had suboptimal vitamin D levels (<20ng/L) at first contact for 
psychosis, a much higher proportion than the previously reported 50% (n=10) with vitamin D 
levels <30ng/ml at FEP (Graham et al., 2015). We identified a mean vitamin D level of 
13.8ng/ml (n=168) at study recruitment, much lower than the previously identified mean 
vitamin D levels in FEP of 28.2 ng/ml (n=20) (Graham et al., 2015), 61.7 ng/ml (n=31) (Yee 
et al., 2016) and 44.8 ng/ml (n=71) (Nerhus et al., 2015).	  This finding may be a reflection of 
the ethnicity distribution of our sample.  
4.5 Strengths and limitations 
A major strength of this study is the prospective study design, allowing for inference to be 
made on the association between vitamin D and total and negative symptoms of psychosis. 
The association between higher vitamin D levels at onset with fewer total and negative 
psychotic symptoms one year later is suggestive of a possible casual association, and the 
longitudinal association reduces the likelihood of reverse causality as an explanation for the 
finding. However, as this is an exploratory study, we did not employ a strategy to account for 
multiple comparisons (Althouse, 2016; Rothman, 1990). Being a hypothesis driven 
exploratory study, we sought to limit the possibility of type II errors (incorrect confirmation of 
the null hypothesis), which multiple testing will increase while reducing the risk of type I 
errors. Further, as clinical symptoms are mutually correlated, the use of Bonferroni 
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correction would not be appropriate as it assumes independence of the performed 
assessments (Bender and Lange, 2001). However, as an exploratory study, our findings 
require replication in large prospective cohorts. There are also several confounding factors 
that we did not control for, including antipsychotic adherence and measures of diet and 
physical activity. In established psychosis lower vitamin D levels are associated with less 
intense physical activity and reduced time spent outdoors(Lally et al., 2016). How this 
translates to FEP populations is not yet clear, and to the best of our knowledge has not been 
investigated(Adamson et al., 2017). Further, we did not identify a significant difference in 
negative symptom scores between those with higher and lower vitamin D levels. The study 
lacked power to confidently detect potential real effects of findings of smaller statistically 
significant difference. Nevertheless, we report on the largest sample size of FEP patients 
with vitamin D data to date, with 168 people included compared to sample sizes ranging 
from 20-71 in earlier cross sectional studies (Graham et al., 2015; Nerhus et al., 2015; Yee 
et al., 2016).  
Conclusion 
Suboptimal vitamin D is highly prevalent in FEP, and remains so 12 months after first contact 
for psychosis. We found that higher baseline vitamin D levels were associated with fewer 
total and negative psychotic symptoms at one year after first contact for psychosis, 
suggesting that vitamin D may have relevance to the course of psychotic disorders. 
Randomised controlled trials to investigate the potential of vitamin D supplementation in 
ameliorating general outcomes, negative symptoms and cognitive impairment in early 
psychosis are called for.  
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